Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European
Go back to Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European| (NASDAQ: SVRA) | Delayed: 5.36 -0.06 (1.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.42 | 52 Week High | $ | |||
| Open | $5.42 | 52 Week Low | $ | |||
| Day High | $5.47 | P/E | N/A | |||
| Day Low | $5.31 | EPS | $ | |||
| Volume | 593,748 | |||||
